Volume 131, Issue 2 pp. 291-297
RESEARCH ARTICLE

Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy for Some but Not All?

William W. Tseng

Corresponding Author

William W. Tseng

Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, California, USA

Correspondence: William W. Tseng ([email protected])

Search for more papers by this author
Francesco Barretta

Francesco Barretta

Unit of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Francesco Tucci

Francesco Tucci

School of Pathology, University of Milan, Milan, Italy

Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy

Search for more papers by this author
Marta Barisella

Marta Barisella

Pathology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy

Search for more papers by this author
Stefano Radaelli

Stefano Radaelli

Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Chiara Colombo

Chiara Colombo

Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Dario Callegaro

Dario Callegaro

Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Carlo Morosi

Carlo Morosi

Deparment of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Roberta Sanfilippo

Roberta Sanfilippo

Deparment of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Chiara Fabbroni

Chiara Fabbroni

Deparment of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Silvia Stacchiotti

Silvia Stacchiotti

Deparment of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Steven H. Sun

Steven H. Sun

Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, California, USA

Search for more papers by this author
Paola Collini

Paola Collini

Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Marco Fiore

Marco Fiore

Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
Alessandro Gronchi

Alessandro Gronchi

Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for more papers by this author
First published: 27 September 2024

ABSTRACT

Background

Pleomorphic liposarcoma (PLPS) is an ultra-rare malignancy distinct from well-differentiated/dedifferentiated and myxoid liposarcoma. In this study, we sought to (1) assess outcomes after surgery for primary, non-metastatic PLPS and (2) explore potential indications for multimodality therapy.

Methods

Clinicopathologic data were retrospectively collected for patients treated from 2002 to 2019 at our sarcoma referral center. Descriptive data were summarized and Kaplan–Meier plots were constructed for overall survival (OS) and crude cumulative incidences (CCI) of disease-specific death (DSD), local recurrence (LR), and distant metastasis (DM). Univariable models were performed to assess the association of specific variables of interest on outcome.

Results

Forty-four pathology-verified PLPS cases were included in this study. Median tumor size was 8.5 cm; 75% were FNCLCC Grade 3. All patients underwent complete resection, including 15 patients (34%) who required re-excision to secure microscopic negative margins. Radiation therapy was given to 75% of patients, chemotherapy in 36%. At 5 years, OS was 75.3%; CCI of DSD, LR, and DM were 17.5%, 2.3%, and 32.5%. Larger tumor size was strongly associated with worse OS (p = 0.028) and DSD (p ≤ 0.001). A subgroup of patients (n = 10, 23%) with smaller, predominantly Grade 2 tumors underwent surgery alone without any LR or DM event at a median follow-up of 7.9 years.

Conclusions

In PLPS, aggressive surgery and when appropriate, radiation therapy, results in excellent local control. Chemotherapy can be considered for larger tumors. Patients with smaller, Grade 2 tumors may be potentially cured with surgery alone.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.